[29] The Radiation Therapy Oncology Group study 0320 evaluated WBRT + stereotactic radiosurgery (SRS)
+ erlotinib and found significant grade 3 — 5 toxicity rates of 49 %, compared with a rate of 11 % for WBRT alone; the toxicities observed included cytopenias, rash, fatigue, and dehydration, among others.